Strong Free Cash Flow Recovery
Operational free cash flow totaled $163 million for the full year, a 57% improvement year-over-year, driven by working capital optimization and disciplined capital allocation.
Completed Corporate Simplification
Successfully completed the spin-off and merger with Controladora Alpek, establishing Alpek as an independent entity with a streamlined corporate structure.
Cash and Balance Sheet Actions
Net debt ended at $1.8 billion (flat vs. prior quarter) and decreased $44 million versus 2024; company executed debt refinancing and maintained committed credit lines to strengthen liquidity.
Footprint Optimization and Expected 2026 Benefits
Ceased PET operations at Cedar Creek and relocated capacity to larger assets; this footprint optimization is expected to yield approximately $20 million of benefit in 2026.
Plastics & Chemicals Sequential Improvement
Plastics & Chemicals comparable EBITDA was $55 million, up 17% sequentially (despite being 50% lower year-over-year), with steady reference margins helping offset softer volumes.
Disciplined CapEx and Lower 2026 CapEx Guidance
Quarterly CapEx was $51 million (annual $170 million); 2026 CapEx guidance set at $130 million reflecting disciplined spending and focus on maintenance and strategic projects.
New Operating Free Cash Flow Guidance
For 2026, Alpek issued an operating free cash flow guidance range of $100 million to $150 million, marking the first time this metric was provided.
Nonstrategic Asset Monetization Pipeline
Four U.S. properties are in advanced stages of sale and could generate approximately $50 million in proceeds (expected mostly in H1 2026), earmarked for deleveraging.
Reasonable 2026 EBITDA Guidance
Base-case comparable EBITDA guidance for 2026 is $450 million to $500 million with upside scenarios (various market improvements) potentially adding ~ $50 million of EBITDA.